INDIANAPOLIS, Oct. 18, 2016 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) today announced an ambitious plan to increase
access to quality health care and to improve long-term health for
millions of people worldwide. Through investments in people,
medicines and health systems, Lilly aims to reach 30 million people
in resource-limited settings annually by 2030. The cornerstone of
this goal – known as Lilly 30x30 – is a new five-year, $90 million investment in the Lilly Global Health
Partnership, which will improve access to treatment for diabetes,
cancer and tuberculosis (TB). One-half of the $90 million commitment will come from the Eli
Lilly and Company Foundation (Foundation); the other half will come
from company funds.
Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/7904651-eli-lilly-global-health-commitment
"Over the last two decades, we have made tremendous progress in
expanding access to quality care in poorer communities, but we can
and must do more. Lilly 30x30 is a company-wide mandate to achieve
a six-fold increase in the number of people we reach annually,
outside of our traditional business," said John C. Lechleiter, Ph.D., Lilly chairman,
president and CEO.
Lechleiter continued, "We will engage the entire Lilly
organization to ensure that our aspirational goals are met. The
investments announced today will help millions more benefit from
Lilly's life-saving work and accelerate our contributions toward
the U.N. Sustainable Development Goals."
Expanded global health partnership to cover more diseases in
more countries
A major component of Lilly 30x30 is a new five-year,
$90 million investment to accelerate
the company's and the Foundation's global health work with key
international, national and local partners. The Lilly Global Health
Partnership will expand current work in diabetes and TB and add
cancer as a new therapeutic area of focus.
Working with expert partners, the Lilly Global Health
Partnership will help people living in communities with limited
resources in Brazil, China, India,
Kenya, Mexico, Russia, South
Africa and the U.S. Lilly will advance its existing global
health work in many of these communities while identifying new
opportunities for partnership. Consistent with the company's
evidence-based approach, the Lilly Global Health Partnership will
research new models of care, report findings and advocate for the
scale-up of the most effective solutions to help more
people.
The Lilly Global Health Partnership includes a new $15 million commitment to the Infectious Disease
Research Institute (IDRI). This new commitment extends an
eight-year collaboration to accelerate early-stage drug discovery
and preclinical development for potential new TB medicines.
"In far too many places around the world, a lack of timely
diagnosis and access to quality care prevents people and
communities from flourishing," said global health expert
Paul Farmer, M.D., Ph.D., who has
collaborated with Lilly on fighting TB since the 1990s. "Lilly's
expansive vision for, and significant commitment to, treating TB in
poor communities is helping to change that. By strengthening health
systems, Lilly's work not only led to important progress on TB but
also laid the groundwork for more integrated care to better
diagnose and treat chronic conditions like diabetes and cancer. We
are grateful for the company's vision and commitment, which have
improved access to care for current and future generations of
patients."
Company-wide goal to help millions more people
Going well beyond philanthropy, Lilly 30x30 will evaluate many
of the company's current business practices to stimulate thinking
for expanding opportunities for medicines to reach more people. To
reach 30 million people annually in communities with limited
resources – a six-fold increase over the number reached today –
Lilly will explore new approaches within different areas of its
business, including:
- Initiatives to strengthen health systems and local treatment
capacity in communities with significant gaps in care
- Patient education programs
- Collaboration on drug discovery for diseases disproportionately
affecting people in resource-limited settings
- Product delivery and packaging more appropriate for people in
resource-limited settings
- Innovative business models, including alternative product
pricing strategies to improve access to care.
The company will regularly report on the progress toward
fulfilling Lilly 30x30 and the specific efforts that contribute to
achieving this goal.
Building on a legacy in global health
The Lilly Global Health Partnership and Lilly 30x30 extend and
accelerate work done through major global health programs supported
by Lilly and the Foundation over the past two decades. These
include the Lilly MDR-TB Partnership, which included a decade-long
transfer of manufacturing technology for TB medicines, support of
early-stage TB drug discovery and improved care in high-burden
countries. In 2011, the Lilly NCD Partnership was launched to help
governments and key stakeholders improve diabetes prevention and
care for people in need. The Lilly Global Health Partnership
encompasses and expands these continuing efforts under a single
heading.
In addition, Lilly works to improve global health through many
other collaborative efforts, including ongoing product donations
and funding for Academic Model Providing Access to Healthcare
(AMPATH) in Kenya; support of the
International Diabetes Federation's Life for a Child program; and
hunger relief efforts.
"Lilly has a strong, 140-year history of improving global health
that goes beyond monetary and product donations," said David A. Ricks, Lilly senior vice president, who
will assume the role of Lilly president and chief executive officer
on January 1, 2017. "As a
research-based company, we bring deep scientific and technical
expertise to develop better solutions for people around the world.
The Lilly Global Health Partnership will enable us to expand our
reach in significant and meaningful ways."
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
www.lilly.com and newsroom.lilly.com/social-channels.
C-LLY
This press release contains forward-looking statements about the
Lilly Global Health Partnership and the Lilly 30x30 program, and
reflects Lilly's current beliefs. However, as with any such
undertaking, there are substantial risks and uncertainties in the
process of implementing the programs under this Partnership. Among
other things, there can be no guarantee that the goals referenced
above will be achieved. For further discussion of these and other
risks and uncertainties, please see Lilly's latest Forms 10-Q and
10-K filed with the U.S. Securities and Exchange Commission. The
company undertakes no duty to update forward-looking
statements.
Refer
to:
|
Edward Sagebiel;
egs@lilly.com; 317-985-6303 (Indianapolis)
|
|
Peter Shelby;
pshelby@lilly.com; +41 79 203 7747 (Geneva)
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-announces-ambitious-new-commitment-to-expand-global-access-to-health-care-300346688.html
SOURCE Eli Lilly and Company